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기관지동맥 색전술 후 객혈의 재발에 관한 연구
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서 론 : 대량객혈은 치료가 이루어 지지 않을 경우, 50% 이상의 사망률을 보이는 호흡기 영역의 가장 위급한 응급상황의 
하나이며 여러 원인에 의해 발생 될 수 있다. 1973년 레미 등에 의해 처음 보고된 이후로 기관지동맥 색전술은 대량의 
재발성 객혈의 치료로 확립되어 그 효과가 입증 되었다.
그러나 기관지동맥 색전술의 재발률은 10~52%로 보고되어 객혈의 재발을 예측 할 수 있는 위험 요소들에 대한 연구가 
필요하다.
재료 및 방법 : 2000년 1월부터 2005년 1월까지 세브란스병원에 100 cc 이상의 대량 객혈로 내원하여 기관지동맥 색전술
을 시행 받은 66명 환자들을 대상으로 하여 기관지동맥 색전술 후 재발의 빈도와 재발과 관련이 있는 위험 요인에 대해 
분석하였다.
결 과 : 5년 간 기관지동맥 색전술을 시행 받은 환자는 75명이었고, 장기간 추적관찰이 되어 결과 분석이 가능했던 환자
는 66명이었다. 이들의 평균 나이는 54.9 ± 15.9세이었고, 남자가 48명, 여자가 18명이었다. 원인 질환은 결핵 20명, 기관지
확장증 및 기타 양성질환 23명, 악성 종양 7명이었고, 평균 20.4개월 간의 추적 관찰 기간 동안 23명(34.9%)에서 치료가 
필요한 대량 객혈이 재발되었다. 환자의 성별과 나이, 이전에 객혈로 시술 받은 과거력, 객혈의 원인 질환, 분포 혈관의 
수 등은 대량 객혈의 재발과 유의한 관계가 없었으나, 병변의 양측성, 흉막 비후, 객혈의 양은 유의한 인자로 관찰되었고, 
로그 회귀분석 결과에서도 동일하였다.
결 론 : 기관지동맥 색전술을 시행한 후 객혈의 재발을 예측할 수 있는 위험 인자로 흉막 비후, 병변의 양측성, 객혈의 
양이 중요하게 작용하며, 이에 대한 대규모 임상 연구가 필요하다.
(Tuberc Respir Dis 2006; 60: 65-71)
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Introduction
When massive hemoptysis is untreated, it has a 
mortality rate of over 50 percents. It is considered 
as one of most dreaded of all respiratory emergen-
cies and can have a variety of underlying causes.
Bronchial artery embolization (BAE) was first 
reported in 1973 by Remy1 and it has become an 
established procedure in the management of massi-
ve and recurrent hemoptysis. Its efficacy is widely 
documented thereafter by number of articles1-11. An 
immediate control of hemoptysis is achieved in 73 
to 98%, with a mean follow of less than one mon-
th1-4. Immediate success rates have increased re-
cently because of the introduction of superselective 
embolization and the refinement of embolic agents 
and techniques4. However, the long-term success 
rate of BAE is known to be unfavorable. Long- 
term recurrence rates are reported to be 10 to 52%, 
with a mean follow up period ranging from one to 
46 months1-7.
The variety of factors influencing that control 
failure has been described.
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Author No. of 
patients
Follow up 
(months)
Recurrence 
rate (%)
Risk factor for recurrence Other variables
Osaki S4 22 46 50
Bronchiectatic change on CT scan,
Pulmonary-bronchial artery shunt
Age, sex, underlying disease, 
morhphologic change, amount of 
hemoptysis, angiographic finding
Yeo DS5 146 6 63 Pleural lesion on chest X-ray Embolic material, underlying disease, feeding vessel, shunt, bilaterality
Kim SO6 75 60 54.5 Underlying disease, amount of bleeding, extent of lung lesion
NR†,
Tamura S8 40 20 60 Pleural thickening on chest X-ray NR†,
Kim BC14 47 72 40
None* Age, sex, bilaterality, shunt, feeding 
artery, neovascularity, underlying 
disease,
Ko DS15 46 12 41.3
Multiple feeding vessel
Incomplete embolization
Previous history of hemoptysis
Hypervascularity, underlying disease, 
age, sex
* No statistically valid risk factor among candidate variables.
† NR = not reported
Table 1. Literature reviews of bronchial artery embolization outcomes
Bronchiectatic change on high resolution CT 
scan (HRCT)4, broncho-pulmonary shunt4, pleural 
thickening5,7, underlying lung diseases6, the amount 
of bleeding8, multiple feeding vessels9, incomplete 
embolization10, and previous hemoptysis history11 
are possible risk factors of recurrent bleeding 
events. But these findings vary from article to 
article and there is not yet a proven condition to 
predict the recurrence.
This study is designed to survey previously do-
cumented possible risk factors of recurrence in tho-
se who underwent BAE in our hospital, during a 
long period. Furthermore, since all patients had 
taken HRCT, we focused on radiological findings 
such as pleural thickening to be possible risk fac-
tors of the recurrence.
Materials and methods
Seventy-five patients underwent bronchial artery 
embolization due to massive hemoptysis more than 
100 cc amount of bleeding in Severance Hospital 
from Jan. 2000 to Jan. 2005. Among them, nine 
patients’ data were not available and could not be 
contacted with. Finally 66 (48 males, 18 females) 
patients’ medical records were analyzed retrospec-
tively with a mean follow up period of 20.4 months 
(ranging from 1 month to 56 months).
The recurrence of massive hemoptysis after BAE 
was defined that a gross hemoptysis more than 100 
cc amount of blood occurred again which needed to 
undergo treatments such as BAE or lung resection 
surgery.
Demographic characteristics such as gender, age, 
the duration of symptom, the amount of hemopty-
sis, previous history of treatment for hemoptysis, 
the main medical condition causing hemoptysis, bi-
laterality of pulmonary lesion, the number of fee-
ding vessels, and the presence of pleural thickening 
were our parameters analyzed. 
For comparison of various risk factors between 
recurrent massive hemoptysis group and controlled 
hemoptysis group, Pearson’s Chi-square test (for n 
> 5) and Fisher’s exact test (for n ≤ 5) were used. 
For continuous variables, Student’s T-test was 
used. Statistical validity is defined if p-value is less 
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Relapsed group Controlled group p-value
Gender
Male 17 31 -
Female 6 12 NS
Total 23 43 -
Age (yrs) 56.5 ± 16.2 54.3 ± 16.2 NS
Duration of symptom (day) 6.3 ± 12.7 8.7 ± 19.5 NS
Amount of hemoptysis (cc) 217 ± 98 153 ± 94 0.008
Previous intervention
Yes (n=9) 5 (55%) 4(45%)
No (n=57) 18 (32%) 39(68%) NS
NS = not significant
Table 2. Demographic features, duration, amount of hemoptysis and previous intervention history
Relapsed group (n=23) Controlled group (n=43) p-value
Active tuberculosis 5(25%) 15(75%)
NS
Malignancies
Primary lung cancer 2(50%) 2(50%)
Metastais to the lung 2(67%) 1(33%)
Other benign diseases
Bronchiectasis 5(26%) 14(74%)
Aspergilloma 8(57%) 6(43%)
Others 1(17%) 5(83%)
* Other diseases include 1 bronchial artery aneurysm, 2 lung abscesses,
and 2 bronchitis
NS = not significant
Table 3. Underlying diseases and previous history of bronchial artery embolzation intervention
than 0.05.
To verify the compounding factors between the 
risk factors whose characters were diverse con-
founding variables, we did multivariate analysis 
using logistic regression analysis with 95% confi-
dence interval.
Results
Among 66 patients whose data were available, 23 
(34.9%) patients had recurred massive hemoptysis 
during a mean follow up period of 20.4 months 
(ranging from 1 month to 54 months). Eight out of 
23 recurred patients had pneumonectomy or lobec-
tomy of lung (3 pneumonectomies and 5 lobecto-
mies) in following event, and remaining 12 patients 
had to undergo another BAE. Four patients died 
due to uncontrolled hemoptysis (one died after pne-
umonectomy).
Concerning the factors influencing relapse, age 
and sex did not play any role and duration of sym-
ptom had not any significance, but the amount of 
hemoptysis had a statistical significance (p =0.008 
by T-test; Table 2).
As to the underlying diseases, we had 20 active 
tuberculosis, 19 benign diseases including 19 bron-
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Relapsed group (n = 23) Controlled group (n = 43) p-value
Bilaterality of lesion
Yes 8(62%) 5 0.008
No 15(28%) 38
Pleural thickening
Present 12(75%) 4 0.001
Absent 11(22%) 39
Number of feeders
1 10(30%) 23(70%) NS
> 1 13(39%) 23(61%)
NS = not significant
Table 4. Radiologic findings and the recurred massive hemoptysis
Variables Odds ratio 95% C.I p-value
Gender MaleFemale
1
0.59 0.53-4.37 NS
Age <50≥50
1
0.42 0.34-2.42 NS
Previous intervention YesNo
1
0.51 0.28-2.76 NS
Underlying disease Active tuberculosis 1
Malignancy 1.76 0.77-11.84 NS
Other benign disease 0.62 0.80-4.86 NS
Duration of symptom ≤ 7days> 7 days
1
1.14 0.16-1.73 NS
Amount of hemoptysis ≤ 200 cc> 200 cc
1
10.21 10.08-50.23 0.008
Bilaterality of lesion NoYes
1
13.93 1.41-138.32 0.018
Number of feeding vessel 1>1
1
2.20 0.36-13.39 NS
Pleural thickening NoYes
1
20.84 3.38-128.45 0.001
NS = not significant
Table 5. Multivariate analysis of different variables
chiectasis, 14 aspergillomas, and 6 others (including 
1 bronchial artery aneurysm, 2 lung abscesses, and 
2 bronchitis), and 7 malignancies (4 primary lung 
cancer and 3 metastatic malignancies), we did not 
find any statistical significance between them (Ta-
ble 3). Nine patients had a history of previous BAE 
treatments for hemoptysis, but they showed no 
increased risk of relapse of major hemoptysis (Ta-
ble 3). Bilateral lesion on radiographic finding and 
pleural thickening on HRCT had increased risk of 
recurred major hemoptysis (p = 0.018 and 0.001, re-
spectively, by Chi-square test and Fisher’s exact 
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test; Table 4). Number of feeding vessels had not 
any statistical value concerning the relapse.
Univariate analysis showed that reliable risk fac-
tors for recurrent hemoptysis after BAE were amo-
unt of hemoptysis, bilaterality of lesion, and pleural 
thickening on HRCT. To verify the compounding 
factors between the risk factors whose characters 
were diverse confounding variables, we did multi-
variate analysis using logistic regression analysis 
with 95% confidence interval. Multivariate analysis 
showed same results as univariate analysis (Table 5).
Discussion
We analyzed the result of BAE in our institution 
during a long period. In previous literatures, long- 
term recurrence rate have been reported to be 10 to 
52%, with a mean follow up period ranging from 
one to 46 months1-11.
Remy et al.1 reported that of 49 patients treated 
for hemoptysis, an immediate arrest was achieved 
in 41, but 34 patients had experienced re-bleeding 
in follow up period beyond the 18 months. Ulfacker 
et al.3 reported that an immediate control of hemop-
tysis was achieved in 33 out of 41 patients (80.5%) 
while hemoptysis recurred in 9 of 33 patients (27.3 
%) in the long-term follow up (mean 24.8 months). 
In our analysis, BAE effectively controlled 65.1% of 
life threatening massive hemoptysis (23 re-blee-
dings in 66 cases) in a mean follow up period of 
20.4 months.
Regarding the factor of recurrence after BAE, 
Osaki et al.4 concluded that bronchiectatic change 
on CT scan and pulmonary-bronchial shunt had 
some statistical significance. Kim et al.6 described 
the underlying lung disease and amount of bleeding 
as reliable risk factors for the recurrence, in a study 
involving 75 patients with a result estimating 54.5 
% of re-bleeding rate after 3 years. But in the stu-
dy of Kim et al14 published 5 years earlier, those 
factors had no significant impact on the recurrence 
of hemoptysis. The former used Caplan-Mayer 
survival analysis with each variable and the latter 
used Chi-square univariate analysis. The diversity 
of previously proposed risk factors may be expla-
ined by variability of their criteria on recurrence, 
sample size, underlying diseases, follow-up time, 
and statistic tool used.
In this study, the amount of hemoptysis had so-
me statistical relation with the recurrent event. 
Though the analysis of underlying disease had no 
statistical significance, active tuberculosis tended to 
have more control rate compared to aspergilloma 
and cancer. The effective anti-tuberculosis drug 
therapy must have reduced the recurrent hemopty-
sis but its relatively modest prevalence in our 
series (30% compared to 43-52% in other domestic 
studies)5,6,12,14 lead to overall no statistical signifi-
cance.
The fact that bilaterlity of lesion on initial chest 
X-ray was higher in relapse group can be explai-
ned by the extent of the lung disease accounts for 
more serious pathology as it was commented by 
Kim et al.6
In 1993, Tamura et al.8 described pleural thicke-
ning as a risk factor for recurrent bleeding after 
BAE. According to them, in the presence of pleural 
thickening, non-bronchial systemic feeder vessels 
that originate from various arteries (e.g., intercos-
tals artery, branches of the subclavian and axillary 
arteries, internal mammary artery and inferior ph-
renic artery) may develop along the pleural surface 
and become enlarged as a result of the inflamma-
tory process. In our study 16 cases showed pleural 
thickening on chest radiography and 12 (75%) of 
them experienced recurrent massive bleeding, whi-
ch was significantly higher than 22% of no pleural 
thickening group.
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This study is a retrospective review of medical 
records, which often should underestimate strength 
of variable. But the presence of pleural thickening 
which had the highest odds ratio can be a reliable 
risk factor for the recurrence of hemoptysis after 
BAE, and this should be verified in a prospective 
study with larger number of patients because this 
study has the limitation caused by small size po-
pulation involved with various underlying diseases.
Summary
Background : 
Hemoptysis, when massive and untreated, has a 
mortality rate of over 50 percents, is considered as 
one of most dreaded of all respiratory emergencies 
and can have a variety of underlying causes.
Bronchial artery embolization (BAE) has become 
an established procedure in the management of ma-
ssive and recurrent hemoptysis, and its efficacy is 
widely documented thereafter by number of arti-
cles.
However, the long-term success rate of BAE is 
known to be unfavorable. Risk factors influencing 
that control failure are inevitably needed.
Materials and methods : 
Seventy-five patients underwent bronchial artery 
embolization due to massive hemoptysis in Seve-
rance Hospital from Jan. 2000 to Jan. 2005. Nine 
patients’ data were not available and could not be 
contacted with. Finally 66 patients’ (48 males, 18 
females) medical records were analyzed retrospec-
tively during a mean follow up period of 20.4 mon-
ths (ranging from 1 month to 54 months).
Results : 
Among 66 patients whose data were available, 23 
(34.9%) patients had recurrent major hemoptysis. 
Patients’ age, sex, underlying disease, previous in-
tervention history, and number of feeding vessels 
had no statistical validity as risk factors of recurred 
major hemoptysis. But bilaterality of lesion, amount 
of hemoptysis, and pleural thickening were revealed 
as meaningful factors for predicting relapse (p = 
0.008, 0.018, and 0.001, respectively).
Conclusion : 
According to our series, patients presenting with 
larger amount of hemoptysis, pleural thickening of 
chest radiography and bilateral lesion are associa-
ted with increased risk of major hemoptysis in pa-
tients treated with BAE.
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